

30,000 Cases of Side Effects Reported from AstraZeneca CoviShield Vaccines in Sweden

By [Great Game India](#)

Global Research, May 17, 2021

[Great Game India](#)

Region: [Europe](#)

Theme: [Science and Medicine](#)

All Global Research articles can be read in 51 languages by activating the “Translate Website” drop down menu on the top banner of our home page (Desktop version).

Visit and follow us on Instagram at [@crg_globalresearch](#).

An official tally of suspected adverse effects resulting from COVID-19 jab has surpassed 30,000 in Sweden. Majority of the [cases are happening in people vaccinated with AstraZeneca's vaccines branded as Covishield](#) in India.

The Scandinavian nation [received](#) 31,844 reports of COVID-19 vaccine side effects as of last week. Three variants of the drug are offered by Sweden.

Recently, 10,460 reports of health issues from Pfizer-BioNTech vaccine and 2,458 from Moderna shot have been received. The side-effects from these 2 shots appear small as compared to 20,563 reports associated with AstraZeneca's Vaxzevria or Covishield.

Fever, headache are the common adverse effects of the vaccine and other reactions include dizziness, joint pain and nausea.

Vaccine	Number of vaccinated individuals	Number of reports received
Comirnaty (Pfizer / BioNtech)	1 856 000	10 460
Covid-19 Modern Vaccine	221 000	2 458
Vaxzevria (Astra Zeneca)	692 000	20 563

Though, the AstraZeneca vaccine has been administered to only 26% of total vaccinated population in Sweden, if we talk about the adverse effect cases, 63% of them are linked to AstraZeneca vaccine.

Out of total 32,000 reports, 663 cases are unclear about which vaccine was administered. General public have submitted two-third of the reports. The agency notified that individual report don't demonstrate any link between the vaccine and the medical episode.

An official with the medical products agency, Ebba Hallberg, told Swedish media that receiving such reports of vaccine adverse effects was unusual, but the figure was high due to public focus on the new vaccines.

Serious side effects are reported by healthcare providers. She said, it was possible that AstraZeneca vaccine was over shown in data as the vaccine was given to many healthcare workers and young people who are tech-savvy and be more likely to report an issue.

The agency got many reports of suspected adverse effects over past months than it does over 4 years, as per one Swedish outlet.

Sweden suspended the use of AstraZeneca's Vaxzevria or Covishield vaccine temporarily in March following reports of blood clots in recipients.

New reports have linked the drug to many other side effects, and even death. A 35-year-old health worker died in Vietnam from anaphylaxis after getting vaccinated.

It has been described as very rare case of side effects linked to vaccine.

Meanwhile, the US is planning to [dump 60 million doses of the AstraZeneca vaccines on India](#) to help us fight COVID-19.

These AstraZeneca or Covishield vaccines however is unapproved for use in the US and

hence the unwanted stock is being offloaded on Indians.

Moreover, this comes at a time when [numerous European countries have stopped or suspended the use of AstraZeneca's vaccine](#) for causing blood clots and are launching lawsuits against the company.

As reported by [GreatGameIndia](#), German scientists have recently found the exact [2 step process how the AstraZeneca COVID-19 vaccine causes blood clots](#) in recipients.

*

Note to readers: Please click the share buttons above or below. Follow us on Instagram, @crg_globalresearch. Forward this article to your email lists. Crosspost on your blog site, internet forums. etc.

Featured image is from GGI

The original source of this article is [Great Game India](#)
Copyright © [Great Game India](#), [Great Game India](#), 2021

[Comment on Global Research Articles on our Facebook page](#)

[Become a Member of Global Research](#)

Articles by: [Great Game India](#)

Disclaimer: The contents of this article are of sole responsibility of the author(s). The Centre for Research on Globalization will not be responsible for any inaccurate or incorrect statement in this article. The Centre of Research on Globalization grants permission to cross-post Global Research articles on community internet sites as long the source and copyright are acknowledged together with a hyperlink to the original Global Research article. For publication of Global Research articles in print or other forms including commercial internet sites, contact: publications@globalresearch.ca
www.globalresearch.ca contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of "fair use" in an effort to advance a better understanding of political, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than "fair use" you must request permission from the copyright owner.

For media inquiries: publications@globalresearch.ca